Biomedical Engineering Reference
In-Depth Information
References
AdAge (2011) U.S. ad spending grew 6.5% in 2010 as auto surged and pharma hit a low, 17 March
2011. Available at
http://adage.com/article/mediaworks/u-s-ad-spending-grew-6-5-2010-auto-
Agarwal R, Bayus BL (2002) The market evolution and sales takeoff of product innovations.
Manag Sci 48(8):1024-1041
Anderson RL, Ortinau DJ (1988) Exploring consumers' post adoption attitudes and use behaviors
in monitoring the diffusion of a technology-based discontinuous innovation. J Bus Res 17(3):
283-298
Atherly A, Rubin PH (2009) The cost-effectiveness of direct-to-consumer advertising for prescrip-
tion drugs. Med Care Res Rev 66(6):639-657
Bass F (1969) A simultaneous equation regression study of advertising and sales of cigarettes.
J Mark Res 6(3):291-300
Bayus B (1992) The dynamic pricing of next generation consumer durables. Mark Sci 11(3):
251-265
Bell RA, Kravitz RL, Wilkes MS (1999) Direct-to-consumer prescription drug advertising and the
public. J Gen Intern Med 14(11):651-657
Berndt ER (2000) International comparisons of pharmaceutical prices: what do we know, and what
does it mean? J Health Econ 19(2):283-287
Berndt ER, Pindyck RS, Azoulay P (2003) Network effects and diffusion in pharmaceutical mar-
kets: antiulcer drugs. J Ind Econ 51(2):243-270
Calfee JE, Winston C, Stempski R (2002) Direct-to-consumer advertising and the demand for
cholesterol-reducing drugs. J Law Econ 45:673-690
Camacho N, Landsman V, Stremersch S (2010) “The Connected Patient.” In
the topic on the
connected customer: The changing nature of consumer and business markets
, Routledge
Academic (Taylor & Francis), ISBN: 9781848728370, 2010, Tilburg Lustrum
Camacho N, Donkers B, Stremersch S (2011) Predictably non-Bayesian: quantifying salience
effects in physician learning about drug quality. Mark Sci 30(2):305-320
Cattin P, Wittink DR (1982) Commercial use of conjoint analysis: a survey. J Mark 46(3):44-53
Caves RE, Whinston MD, Hurwirz MA (1991) Patent expiration, entry, and competition in the
U.S. pharmaceutical industry. Brookings Papers on Economic Activity 1-48
Chintagunta PK, Desiraju R (2005) Strategic pricing and detailing behavior in international mar-
kets. Mark Sci 24(1):67-80
Chintagunta P, Jin G, Jiang K (2009) Information, learning, and drug diffusion: the case of Cox-2
inhibitors. Quant Mark Econ 7(4):399-443
Coleman JS, Katz E, Menzel H (1966)
Medical innovation: A diffusion study
. Indianapolis:
Bobbs-Merrill
Corstjens M, Demeire E, Horowitz I (2005) New product success in the pharmaceutical industry:
how many bites at the cherry? Econ Innov New Technol 14(4):319-331
Coscelli A, Shum M (2004) An empirical model of learning and patient spillovers in new drug
entry. J Econom 122(2):213-246
Crawford GS, Shum M (2005) Uncertainty and learning in pharmaceutical demand. Econometrica
73(4):1137-1173
Dahan E, Hauser JR (2002) The virtual customer. J Prod Innov Manag 19(5):332-353
Danaher P, Hardie P, Putsis W (2001) Marketing-mix variables and the diffusion of successive
generations of a technological innovation. J Mark Res 38(4):501-514
Danzon PM, Chao LW (2000a) Cross-national price differences for pharmaceuticals: how large,
and why? J Health Econ 19(2):159-195
Danzon PM, Chao LW (2000b) Does regulation drive out competition in pharmaceutical markets?
J Law Econ 43(2):311-357
Danzon PM, Furukawa MF (2003) Prices and availability of pharmaceuticals: evidence from nine
countries. Health Aff 22(6):521-536
Search WWH ::
Custom Search